External Quality Assessment Exercise Highlights the Limits of Automation and the Microbiologist’s Role in Safe Diagnosis
Clinical microbiology is in a constant state of evolution, and the genus Phytobacter illustrates how a microorganism can remain under the radar of laboratories for years. Phenotypically similar to Pantoea, Kluyvera, and Enterobacter, it was long misclassified. Only with advances in genomic tools has it become possible to recognize its true significance as an opportunistic pathogen.
Historical evidence shows that sepsis outbreaks in the United States in the 1970s and in Brazil in 1997, 2000, 2010, and 2013—initially attributed to Enterobacter agglomerans or Pantoea spp.—were in fact caused by Phytobacter diazotrophicus. Revisiting these cases raised a red flag about the overreliance on automated identification systems or manual methods using outdated databases, without critical analysis by the microbiologist.
This story is revisited in a documentary that examines the Brazilian outbreak and the process of re-evaluating the isolates, featuring expert testimonies and behind-the-scenes insights into the investigation that led to the pathogen’s reclassification.
From the Environment to the Hospital
Originally found in soil and plant microbiomes, Phytobacter fits within the One Health framework. Its adaptability allows it to persist in hospital environments, particularly in water systems and intravenous solutions. Biofilm formation resistant to chlorination facilitates its spread and increases risk for immunocompromised patients.
Moreover, recent clinical isolates have shown high-impact resistance genes, including blaKPC, blaNDM-1, and blaIMP, often carried on mobile plasmids. This profile positions the genus as a potential reservoir of antimicrobial resistance, with direct implications for therapy and infection control.
What the Quality Exercise Revealed in Practice
In an External Quality Assessment (AEQ) conducted by Controllab in partnership with Lacen/PR, an anonymized sample containing Phytobacter diazotrophicus was sent to hundreds of laboratories. Most participants misidentified the microorganism as Pantoea spp., particularly when using automated systems based on biochemical panels with outdated databases.
The error is not merely taxonomic. It can lead to underestimating clinical risk, hinder outbreak detection, and influence therapeutic decisions. MALDI-TOF platforms with updated databases performed better, underscoring the importance of keeping these tools current.
Detailed results of this exercise are presented in a new technical publication (Laes & Haes, issue 279, p. 72–84), including a comparative analysis of identification methods and implications for routine laboratory practice.
Automation Requires a Critical Eye
Automation has undeniably advanced microbiology, but the data show it cannot replace expert interpretation. Inconsistent profiles—such as isolates identified as Pantoea with a positive indole test or an identification probability below 98%—should be treated as warning signs.
For Dr. Marcelo Pillonetto, scientist at the Laboratório Central do Paraná (Lacen/PR) and professor at PUCPR, the case of Phytobacter illustrates a growing challenge. “Relying solely on equipment results can mask clinically relevant pathogens. Integration of automation, updated MALDI-TOF, and critical microbiologist analysis is what ensures a safe and actionable diagnosis for the clinical team,” he says.
Pathways to Risk Reduction
Experts highlight priority actions for laboratories:
• Periodic updates of automated system and MALDI-TOF databases;
• Critical review of isolates from sterile sites identified as Pantoea spp.;
• Use of molecular methods for confirmation in critical cases;
• Ongoing training in taxonomy and microbiological interpretation.
Accurate Diagnosis Means Patient Safety
The high rate of misidentification of Phytobacter diazotrophicus reveals a real risk for epidemiological surveillance and patient care. Recognizing this pathogen goes beyond taxonomic discussion: it strengthens infection control, guides therapeutic decisions, and helps monitor the advance of antimicrobial resistance in today’s clinical laboratory landscape.
